Solventum Co. (NYSE:SOLV) Shares Sold by Amundi

Amundi reduced its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 13.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 669,116 shares of the company's stock after selling 102,651 shares during the quarter. Amundi owned approximately 0.39% of Solventum worth $46,142,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in SOLV. Modus Advisors LLC acquired a new stake in shares of Solventum in the 4th quarter valued at about $25,000. Stonebridge Financial Group LLC acquired a new stake in shares of Solventum in the 4th quarter valued at about $26,000. True Wealth Design LLC boosted its position in shares of Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company's stock valued at $33,000 after purchasing an additional 471 shares during the period. Crews Bank & Trust acquired a new stake in shares of Solventum in the 4th quarter valued at about $32,000. Finally, Prospera Private Wealth LLC acquired a new stake in shares of Solventum in the 3rd quarter valued at about $35,000.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on SOLV shares. Piper Sandler upped their target price on Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. Mizuho upped their price objective on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. The Goldman Sachs Group upped their price objective on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Bank of America upped their price objective on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company upped their price objective on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $79.86.

Remove Ads

Solventum Stock Performance

Shares of SOLV stock opened at $73.95 on Thursday. The company has a market cap of $12.79 billion and a price-to-earnings ratio of 26.89. The stock has a 50 day simple moving average of $74.24 and a 200-day simple moving average of $70.96. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.